Archive | News

Technical.ly Baltimore: UMB Licenses Technology to Y Combinator-backed Biotech Startup

Ritu_headshot_2019-e1575410514124

A biotech startup that’s backed by Silicon Valley’s well-known Y Combinator accelerator has ties to Baltimore: GEn1E Lifesciences is working to commercialize a treatment for inflammatory and age-related diseases that was developed at the University of Maryland, Baltimore, and is partnering with a Baltimore-based startup that also grew out of UMB collaboration. On Tuesday, UMB said it granted GEn1E Lifesciences the […]

Comments Off on Technical.ly Baltimore: UMB Licenses Technology to Y Combinator-backed Biotech Startup Continue Reading →

BioBuzz: For 20 Years This Company Has Helped to Shape the Field of Cell Therapy

Maxcyte logo square

How MaxCyte Has Evolved to Become Leading Technology Provider for Cell Engineering and Leveraged Its Flow Electroporation® Technology and Know-How to Launch Its Own Robust CAR Pipeline  MaxCyte, located in Gaithersburg, Maryland, is a unique biotech company that is a key anchor of the robust and growing Maryland cell and gene therapy industry. Founded in 1999, […]

Comments Off on BioBuzz: For 20 Years This Company Has Helped to Shape the Field of Cell Therapy Continue Reading →

Technical.ly Baltimore: Illumina Opens Training Center at University of Maryland BioPark

UMBioPark-Twitter-Profile-Image

The San Diego genomics leader is expecting the facility to host hundreds of customers and employees each year. Illumina’s first East Coast location is officially open in Baltimore. On Tuesday, the San Diego-based genomics leader celebrated the grand opening of its new facility at the University of Maryland BioPark, the 14-acre research and technology park located to […]

Comments Off on Technical.ly Baltimore: Illumina Opens Training Center at University of Maryland BioPark Continue Reading →

Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965

Indalo

Key milestone reached in adaptive Phase 1/1b clinical trial that began in April 2019 Cambridge, MA, October 21, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), today announced that the first IPF patient has been […]

Comments Off on Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965 Continue Reading →

CoapTech LLC Awarded $1.2M Grant from National Institutes of Health to Support Clinical Evaluation and Training for Novel PUMA-G Device

coaptech logo

BALTIMORE, Md., Oct. 21, 2019 (GLOBE NEWSWIRE) — CoapTech LLC announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health (NIH) awarded the company a two-year, $1.2M R44 Small Business Innovation Research (SBIR) Phase II grant on August 29, 2019. This builds on a $225,000 Phase […]

Comments Off on CoapTech LLC Awarded $1.2M Grant from National Institutes of Health to Support Clinical Evaluation and Training for Novel PUMA-G Device Continue Reading →

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

MAXCYTE-New-Logo-2016-LARGE

CAMBRIDGE, Mass., and GAITHERSBURG, Md., – October 7, 2019:– Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell […]

Comments Off on Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines Continue Reading →

KaloCyte Relocates to Downtown Baltimore as Co-Founders Join University of Maryland Faculty

Kalocyte

Biotechnology Company Is Developing Synthetic Blood Product for Use in Trauma Settings BALTIMORE, Sept. 23, 2019 /PRNewswire/ — KaloCyte, a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, has joined Baltimore’s growing biotech community as a University of Maryland […]

Comments Off on KaloCyte Relocates to Downtown Baltimore as Co-Founders Join University of Maryland Faculty Continue Reading →

BioBuzz: GlycoMimetics CEO Rachel King Among Female Execs Setting Standard of Excellence in Biohealth Capital Region

RachelKing

Liftstream, a U.K.-based executive recruiting firm, released an oft referenced report called “A Public Reality for Women in Biotech Boardrooms” in 2016. Lifstream’s research found that only 7 to 9 percent of biotech CEOs were women, less than 11 percent of board seats were held by females and 98 percent of board chair positions were held by […]

Comments Off on BioBuzz: GlycoMimetics CEO Rachel King Among Female Execs Setting Standard of Excellence in Biohealth Capital Region Continue Reading →

GlycoMimetics CEO Rachel King Featured in Article on Uproleselan

RachelKing

In Cancer, Boosting Chemotherapy while Reducing Toxic Side Effects is a Potential Breakthrough GlycoMimetics is conducting a pivotal Phase 3 trial in the US, Europe and Australia to determine if its drug candidate, uproleselan, can successfully treat patients with relapsed and refractory acute myeloid leukemia (AML), a blood cancer. The unique aspect of uproleselan is […]

Comments Off on GlycoMimetics CEO Rachel King Featured in Article on Uproleselan Continue Reading →

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

MAXCYTE-New-Logo-2016-LARGE

–      No dose-limiting toxicities or safety concerns observed in first cohort of treated patients–      Feasibility of streamlined, faster CAR therapy manufacturing process confirmed–      Dosing initiated in second cohort of patients Gaithersburg, Maryland – May 8, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it […]

Comments Off on MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform Continue Reading →